Found 541783 clinical trials
Sort by:
Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People
Not yet recruiting
- Conditions
- Inherited Cardiac ConditionsSudden Cardiac ArrestVentricular ArrhythmiaAthleteVentricular Fibrillation
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 40
- Registration Number
- NCT07014579
- Locations
- 🇬🇧
Glenfield Hospital, Leicester, Leicestershire, United Kingdom
Complications Associated With Delayed Admission to Spinal Injury Unit
Not yet recruiting
- Conditions
- Spinal Cord InjuryDelayed Admission
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust
- Target Recruit Count
- 1400
- Registration Number
- NCT07015099
- Locations
- 🇬🇧
The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
Phase 2
Not yet recruiting
- Conditions
- Healthy Subjects
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Cerus Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT07015437
- Locations
- 🇺🇸
American Red Cross Research Laboratory, Norfolk, Virginia, United States
Evaluation of the Analgesic Efficacy of an Ultrasound-guided Transperineal Pudendal Block in Outpatient Hemorrhoidal Surgery
Not Applicable
Not yet recruiting
- Conditions
- Hemorrhoids
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
- Target Recruit Count
- 202
- Registration Number
- NCT07015775
- Locations
- 🇫🇷
Hôpital Privé Claude Galien, Quincy-sous-Sénart, France
Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Completed
- Conditions
- Oral Squamous Cell Carcinoma (OSCC)
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Commonwealth Healthcare Corporation
- Target Recruit Count
- 31
- Registration Number
- NCT07015333
- Locations
- 🇲🇵
CHCC, Saipan, Northern Mariana Islands
Integrating Inuit Knowledge Principles in Multi-Level Mental Health Clinical Trials
Early Phase 1
Not yet recruiting
- Conditions
- Depression, Anxiety
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT07014852
- Locations
- 🇨🇦
Aqqiumavvik Society, Arviat, Nunavut, Canada
🇨🇦Aqqiumavvik - Arviat Wellness Society, Arviat, Nunavut, Canada
An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults
Phase 1
Not yet recruiting
- Conditions
- Klebsiella Pneumoniae InfectionVaccine
- Interventions
- Biological: Glyconjugate Klebsiella pneumoniae bivalent vaccine
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Cho Pharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT07016152
- Locations
- 🇨🇳
National Taiwan University Hospital- Clinical Trial Center, Taipei, Taiwan
Tomoelastography in Predicting Postoperative Pancreatic Fistula
Completed
- Conditions
- Pancreatectomy
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 157
- Registration Number
- NCT07014800
- Locations
- 🇨🇳
Shi Siya, Guangzhou, Guangdong, China
Therapeutic Efficacy of Cutaneous Application of Postbiotic N-(1-carbamoyl-2-phenyl-ethyl) Butyramide (FBA) in Pediatric Subjects Affected by Atopic Dermatitis
Not Applicable
Recruiting
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 100
- Registration Number
- NCT07016087
- Locations
- 🇮🇹
Department of Traslational Medical Science - University of Naples Federico II, Naples, Italy
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 65
- Registration Number
- NCT07015242
- Locations
- 🇺🇸
Local Institution - 307, Stanford, California, United States
🇺🇸Local Institution - 305, Aurora, Colorado, United States
🇺🇸Local Institution - 308, Tampa, Florida, United States